Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 6:19 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 28 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: SIRT Clear all
Completed No phase listed Observational

Measurement of Pro-angiogenic Markers in Patients With Hepatic Metastases Undergoing SIRT

NCT00994370
View directory record Official record
Conditions
Liver Cancer
Interventions
Not listed
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 85 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 20, 2014 · Synced Oct 19, 2026, 6:19 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

ACEs, SIRT1, and Premature Vascular Aging in Humans

NCT07073352
View directory record Official record
Conditions
Adverse Childhood Experiences, Endothelial Dysfunction
Interventions
Nicotinamide Riboside, Placebo
Dietary Supplement
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 30 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
2
States / cities
Iowa City, Iowa • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 19, 2026, 6:19 AM EDT
Completed Phase 1Phase 2 Interventional

Sirtuin-NAD Activator in Alzheimer's Disease

NCT05040321
View directory record Official record
Conditions
Alzheimer's Disease (Incl Subtypes), Dementia
Interventions
MIB-626, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
55 Years to 85 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 19, 2026, 6:19 AM EDT
Active, not recruiting Not applicable Interventional

Selective Internal Radiation Therapy (SIRT) Using SIR-Spheres® Y-90 Resin Microspheres on DoR & ORR in Unresectable Hepatocellular Carcinoma Patients

NCT04736121
View directory record Official record
Conditions
Unresectable Hepatocellular Carcinoma, BCLC Stage A Hepatocellular Carcinoma, BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma
Interventions
Resin microspheres containing yttrium-90 (Y-90)
Device
Lead sponsor
Sirtex Medical
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
22
States / cities
Los Angeles, California • Orange, California • Miami, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Oct 19, 2026, 6:19 AM EDT
Active, not recruiting Phase 1 Interventional

SIRT With Tremelimumab and Durvalumab for Resectable HCC

NCT05701488
View directory record Official record
Conditions
Resectable Hepatocellular Carcinoma, Hepatocellular Carcinoma, Hepatocellular Cancer
Interventions
Durvalumab, Tremelimumab, SIRT
Drug · Device
Lead sponsor
Jiping Wang, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
Los Angeles, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 19, 2026, 6:19 AM EDT
Recruiting Phase 2 Interventional

Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio

NCT05655949
View directory record Official record
Conditions
Bile Duct Cancer, Cholangiocarcinoma, Cholangiocarcinoma Non-resectable, Cholangiocarcinoma Metastatic, Metastatic Intrahepatic Cholangiocarcinoma
Interventions
Gemcitabine, Cisplatin, Durvalumab, Yttrium-90
Drug · Radiation
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 19, 2026, 6:19 AM EDT
Completed Phase 1 Interventional

Study of Capecitabine in Combination With SIR-Spheres in Patients With Advanced Cancer

NCT00604409
View directory record Official record
Conditions
Metastatic Liver Cancer
Interventions
SIRT, capecitabine
Radiation · Drug
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 7, 2015 · Synced Oct 19, 2026, 6:19 AM EDT
Recruiting Phase 2 Interventional

RESvEraTrol in Parkinson's Disease (RESET)

NCT07592767
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Trans-Resveratrol
Drug
Lead sponsor
Georgetown University
Other
Eligibility
55 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 19, 2026, 6:19 AM EDT
Not listed Phase 1 Interventional

Basis: Evaluating Sirtuin Supplements To Benefit Elderly Trauma Patients (BES2T BET)

NCT03635411
View directory record Official record
Conditions
Recovery of Function
Interventions
Nicotinamide Riboside and Pterostilbene, Placebo
Dietary Supplement
Lead sponsor
Elysium Health
Industry
Eligibility
65 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 6, 2020 · Synced Oct 19, 2026, 6:19 AM EDT
Completed Phase 1 Interventional

Selective Internal Radiation Therapy (SIRT) in Patients With Unresectable Colorectal Cancer Liver Metastases Who Failed Prior Intraarterial Pump Chemotherapy

NCT00972036
View directory record Official record
Conditions
Colon Cancer, Rectal Cancer
Interventions
SIR-spheres® (Selective Internal Radiation Therapy)
Device
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 11, 2014 · Synced Oct 19, 2026, 6:19 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

SIRT Followed by CIS-GEM Chemotherapy Versus CIS-GEM Chemotherapy Alone as 1st Line Treatment of Patients With Unresectable Intrahepatic Cholangiocarcinoma

NCT02807181
View directory record Official record
Conditions
Intrahepatic Cholangiocarcinoma
Interventions
Cisplatin-gemcitabine, Radiation: SIRT + chemotherapy (cisplatin-gemcitabine)
Drug · Device
Lead sponsor
Sirtex Medical
Industry
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Spokane, Washington
Source: ClinicalTrials.gov public record
Updated May 9, 2025 · Synced Oct 19, 2026, 6:19 AM EDT
Completed Phase 2 Interventional Results available

Safety Study of Regorafenib and SIR-Spheres® Microspheres Radioembolization in Patients With Refractory Metastatic Colorectal Cancer With Liver Metastases

NCT02195011
View directory record Official record
Conditions
Colorectal Neoplasms
Interventions
SIR-Spheres, Regorafenib
Device · Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
3
States / cities
St. Petersburg, Florida • Kansas City, Missouri • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 5, 2023 · Synced Oct 19, 2026, 6:19 AM EDT
Completed No phase listed Observational

Evaluating the Effects of Selective Treatment Utilizing Flex-dosing for Unresectable HCC With Y90 SIR-Spheres

NCT04903548
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
SIRT with Y-90 resin microspheres
Procedure
Lead sponsor
Methodist Health System
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Oct 19, 2026, 6:19 AM EDT
Terminated Phase 2 Interventional Results available

The Effect of Nicotinamide Riboside on Skeletal Muscle Function in Heart Failure Subjects

NCT03565328
View directory record Official record
Conditions
Heart Failure
Interventions
Nicotinamide Riboside
Dietary Supplement
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 75 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
2
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 28, 2020 · Synced Oct 19, 2026, 6:19 AM EDT
Not listed Phase 2 Interventional

Chemotherapy and Internal Radiation in Treating Patients With Colorectal Cancer That Has Spread to the Liver

NCT00408551
View directory record Official record
Conditions
Colorectal Cancer, Metastatic Cancer
Interventions
floxuridine, fluorouracil, irinotecan hydrochloride, leucovorin calcium, oxaliplatin
Drug
Lead sponsor
Goshen Health System
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Goshen, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 19, 2013 · Synced Oct 19, 2026, 6:19 AM EDT
Completed Not applicable Interventional Results available

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

NCT00724503
View directory record Official record
Conditions
Colorectal Cancer, Colorectal Carcinoma, Liver Metastases
Interventions
SIR-Spheres yttrium-90 microspheres, Systemic chemotherapy (FOLFOX)
Device · Drug
Lead sponsor
Sirtex Medical
Industry
Eligibility
18 Years and older
Enrollment
530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
21
States / cities
Scottsdale, Arizona • Duarte, California • North Miami Beach, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2019 · Synced Oct 19, 2026, 6:19 AM EDT
Active, not recruiting Not applicable Interventional

Combined Y-90 Selective Internal Radiation Therapy (Y-90 SIRT) and Stereotactic Body Radiation Therapy (SBRT) in Hepatic Malignancy.

NCT04518748
View directory record Official record
Conditions
Liver Malignancy
Interventions
Yttrium-90, Selective Internal Radiation Therapy, Stereotactic Body Radiation Therapy
Device · Radiation
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 19, 2026, 6:19 AM EDT
Completed No phase listed Observational

Effect of Fasting and Refeeding on T-cell Fate

NCT02719899
View directory record Official record
Conditions
Asthma, Inflammation
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
21 Years to 37 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 29, 2025 · Synced Oct 19, 2026, 6:19 AM EDT
Completed Not applicable Interventional Results available

Comparison of Yttrium-90 Absorbed Doses Using PET/CT Versus PET/MR Imaging for Hepatic Malignancies

NCT04332419
View directory record Official record
Conditions
Hepatic Malignancies
Interventions
PET/CT, PET/MR, SIRT with Y-90
Device · Radiation
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 22, 2022 · Synced Oct 19, 2026, 6:19 AM EDT
Terminated Not applicable Interventional Results available

SIR-Spheres® for the Treatment of Unresectable Hepatocellular Carcinoma

NCT00503867
View directory record Official record
Conditions
Carcinoma, Hepatocellular, Hepatoma
Interventions
SIR-Spheres microspheres
Device
Lead sponsor
Sirtex Medical
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
4
States / cities
Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2020 · Synced Oct 19, 2026, 6:19 AM EDT
Terminated Not applicable Interventional Results available

Yttrium-90 Radioembolization With Glass Microspheres (TheraSphere) for Patients With Hepatocellular Carcinoma

NCT01290523
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Selective internal radiation therapy of the liver with Yttrium-90 glass microspheres (TheraSphere)
Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 13, 2019 · Synced Oct 19, 2026, 6:19 AM EDT
Withdrawn Phase 2 Interventional

Mechanisms of Metabolic Regulation of Resveratrol on Humans With Metabolic Syndrome

NCT00654667
View directory record Official record
Conditions
Insulin Resistance
Interventions
Placebo, Resveratrol
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
50 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 4, 2015 · Synced Oct 19, 2026, 6:19 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Practicality of Intermittent Fasting and Its Effect on Markers of Aging and Oxidative Stress

NCT02132091
View directory record Official record
Conditions
Aging, Metabolism
Interventions
Intermittent Fasting, 400 IU Vitamin E, 1000 mg Vitamin C
Other · Dietary Supplement
Lead sponsor
University of Florida
Other
Eligibility
19 Years to 30 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Dec 14, 2015 · Synced Oct 19, 2026, 6:19 AM EDT
Completed Not applicable Interventional Results available

Yttrium-90 (Y90) Glass Microspheres PET/CT in Imaging Patients With Liver Tumors

NCT03109262
View directory record Official record
Conditions
Primary Malignant Liver Neoplasm
Interventions
Computed Tomography (CT), Positron Emission Tomography (PET), 90-Yttrium (Y-90) Glass Microspheres, Technetium 99mTc albumin aggregated (99mTc-MAA), Single-photon emission computerized tomography (SPECT) scan
Procedure · Device · Diagnostic Test
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jan 10, 2022 · Synced Oct 19, 2026, 6:19 AM EDT